Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | June 20, 2023 | June 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date June 20, 2023 · Filed June 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.14 · Expires 2033-06-19 | Direct | 20,200 |
Reported balance
After 2023-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 20,200 · Balance 20,200 F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2023 Filed Jun 22, 2023 16:27 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 20,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001209191-23-039063 · doc4.xml · derivative · entry 1 Canamasas Itziar · CIK 0001921346 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,200 Underlying: Common Stock · 20,200 shares Expires 2033-06-19 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the 20th day of the month, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 20:40 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $6.67 | $0.00 |
DisclosureSEC source: 0001209191-22-037649 · doc4.xml · derivative · entry 1 Canamasas Itziar · CIK 0001921346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| April 11, 2022 Filed Apr 14, 2022 19:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 24,009 | $0.00 Strike: $16.79 | $0.00 |
DisclosureSEC source: 0001209191-22-024484 · doc4.xml · derivative · entry 1 Canamasas Itziar · CIK 0001921346 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,009 Underlying: Common Stock · 24,009 shares Expires 2032-04-11 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on May 11, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.